Compare · HBIO vs PKI
HBIO vs PKI
Side-by-side comparison of Harvard Bioscience Inc. (HBIO) and PerkinElmer Inc. (PKI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HBIO and PKI operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- PKI is the larger of the two at $21.38B, about 784.9x HBIO ($27.2M).
- HBIO has hit the wire 2 times in the past 4 weeks while PKI has been quiet.
- PKI has more recent analyst coverage (17 ratings vs 2 for HBIO).
- Company
- Harvard Bioscience Inc.
- PerkinElmer Inc.
- Price
- $6.20-3.58%
- $115.23-0.88%
- Market cap
- $27.2M
- $21.38B
- 1M return
- -11.43%
- -
- 1Y return
- +5.46%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- News (4w)
- 2
- 0
- Recent ratings
- 2
- 17
Harvard Bioscience Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.
PerkinElmer Inc.
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Latest HBIO
- Harvard Bioscience Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Harvard Bioscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.
- SEC Form 10-Q filed by Harvard Bioscience Inc.
- Harvard Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Harvard Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Harvard Bioscience Announces First Quarter 2026 Financial Results
- Harvard Bioscience to Participate in Upcoming Investor Conferences
- Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
- SEC Form DEFA14A filed by Harvard Bioscience Inc.
Latest PKI
- Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)
- Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Klobuchar Michael A was granted 481 shares (SEC Form 4)
- Vandebroek Sophie V. was granted 481 shares (SEC Form 4)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- Singh Prahlad R. exercised 57,039 shares at a strike of $76.83, sold $2,212,480 worth of shares (21,217 units at $104.28) and covered exercise/tax liability with 15,424 shares, increasing direct ownership by 25% to 103,414 units (SEC Form 4)
- Victor Miriame exercised 2,408 shares at a strike of $105.62 and covered exercise/tax liability with 1,030 shares, increasing direct ownership by 15% to 10,470 units (SEC Form 4)